Press release

Know Labs Announces Formation of Advisory Board

Sponsored by Businesswire

Labs, Inc.
(OTCQB: KNWN) – a creator and provider of diagnostic
solutions, announced today the formation of its Medical, Scientific and
Regulatory Advisory Board, the initial members of the Advisory Board and
its first meeting.

This press release features multimedia. View the full release here:

Alexander (Zan) Fleming, M.D. (Photo: Business Wire)

Alexander (Zan) Fleming, M.D. (Photo: Business Wire)

The Advisory Board was formed to provide counsel and guidance to the
Company and its senior management, CEO Phil Bosua and Chairman and
Founder, Ron Erickson. The Advisory Board is chaired by Know Labs Chief
Medical Officer, James (Andy) Anderson, M.D.

The initial members of the Advisory Board in addition to Dr. Anderson
are G. Alexander (Zan) Fleming, M.D. and David C. Klonoff, M.D.

In assembling the Know Labs Advisory Board, Dr. Anderson remarked, “I
wanted to bring together a team of experienced diabetes, obesity and
cardiovascular disease experts who can guide us as we bring the
remarkable Know Labs technology to the market. I have no doubt we will
be successful and will make a significant difference in people’s lives.
I look forward to the active engagement of the Advisory Board as we
progress toward approval and launch of our first group of non-invasive
UBAND wearable devices including the UBAND Calorie Counter and the first
truly non-invasive UBAND Continuous Glucose Monitor. Our just concluded
meeting at the Know Labs laboratory was extremely productive. We are all
excited by the promise of the Know Labs technology in diabetes and
cardiometabolic disease, and the future expansion into additional health
and wellness, and medical therapeutic areas.”

Dr. Fleming, speaking for the group, said, “We were drawn to Know Labs
by their innovative technology and their exuberant commitment to success
as well as our long term trusted working relationship with Andy
Anderson. We leave our first meeting full of energy and enthusiasm for
the Know Labs technology, its team and its application to human health
and diagnostics. We will give laser focus to assisting with bringing the
UBAND CGM to market as soon as possible.”

The backgrounds of the members of the Advisory Board provide a broad
breadth and depth of experience to guide Know Labs as it first
introduces its non-invasive wearable UBAND Calorie Counter to then be
followed by submission to the US Food and Drug Administration of its
non-invasive wearable UBAND Continuous Glucose Monitor.

Alexander (Zan) Fleming, M.D.

Dr. Fleming is President and Chief Executive Officer of Tolerion, a
biotechnology company developing disease-modifying treatments for Type 1
diabetes and other autoimmune diseases. He is also Founder and Executive
Chairman of Kinexum, a company of professionals from across the world
with diverse expertise in developing drugs, biotech products, medical
devices and digital health technologies. Dr. Fleming received his M.D.
and internal medicine training from Emory University, fellowship
training in endocrinology at Vanderbilt University and metabolism at
National Institutes of Health, where he was a senior fellow.

At the US Food and Drug Administration from 1986-98, Dr. Fleming was
responsible for the therapeutic areas of diabetes, other metabolic and
endocrine disorders, growth and development, nutrition, lipid-lowering
compounds, and reproductive indications. He led reviews of landmark
approvals including metformin, as well as the first statin, human
insulin analog, PPAR-agonist, and growth hormone for non-GH deficiency
indications. Dr. Fleming oversaw clinical review of the earliest biotech
products including human insulin and growth hormone. He helped to shape
FDA policies and practices related to therapeutic review and regulatory
communication. He was a major contributor to FDA’s Good Review Practice
(GRP) initiative and led the committee responsible for education and
training at CDER. He conceived and directed the first FDA pilot project
to utilize the internet for regulatory communication.

Dr. Fleming’s regulatory and technical expertise has been requested in
numerous international settings including the World Health Organization,
where he was on assignment from FDA during 1991-92. Dr. Fleming was a
member of the expert working groups on Good Clinical Practices and
General Considerations for Clinical Trials of the International
Conference on Harmonization (ICH) and participated on other ICH
committees including the Common Technical Document working group.

Dr. Fleming is lead author of the book, Optimizing Development of
Therapies for Diabetes
. He has frequently published scientific
articles and book chapters, the most recent chapter, “Regulatory
Considerations for Early Clinical Development,” is in Translational
Research Methods for Diabetes, Obesity and Cardiometabolic Drug
, published by Springer in January 2019. He has been a
member of many corporate and advisory boards to academic and commercial
institutions and professional societies. He serves on the joint
technology working groups of the European Association for the Study of
Diabetes and American Diabetes Association.

Dr. Fleming coined the term, Metabesity, which refers to the
constellation of diabetes, obesity, cardiovascular disease,
neurodegenerative and the aging process itself, all of which share
common metabolic root causes and potential preventive therapies. He
organized the first Congress on Metabesity in London in October 2017,
which will be followed by the second Congress in Washington, D.C. in

David C. Klonoff, M.D.

Dr. Klonoff is a practicing endocrinologist specializing in the
development and use of diabetes technology. He is Medical Director of
the Dorothy L. and James E. Frank Diabetes Research Institute of
Mills-Peninsula Medical Center in San Mateo, California and a Clinical
Professor of Medicine at UCSF. Dr. Klonoff is a graduate of UC Berkeley
(junior year Phi Beta Kappa) and UCSF Medical School (junior year Alpha
Omega Alpha). His postgraduate training in internal medicine and
endocrinology included two years at UCLA Hospital and three years at
UCSF Hospital.

Dr. Klonoff coined the term “diabetes technology”. He received an FDA
Director’s Special Citation Award in 2010 for outstanding contributions
related to diabetes technology. In 2012 Dr. Klonoff was elected as a
Fellow of the American Institute of Medical and Biological Engineering
(AIMBE) and cited as among the top 2% of the world’s bioengineers for
his engineering work in diabetes technology. He received the 2012 Gold
Medal Oration and Distinguished Scientist Award from the Dr. Mohan’s
Diabetes Specialities Centre and Madras Diabetes Research Foundation of
Chennai, India. Dr. Klonoff was invited to speak to the US Congressional
Diabetes Caucus in 2017, participate in the White House Health and
Cybersecurity Roundtable in 2015, and speak at the European Parliament
in 2010.

Dr. Klonoff is the Founding Editor-in-Chief of Journal of Diabetes
Science and Technology
. He has authored over 200 articles in
PubMed-indexed journals and has been a Principal Investigator on over
110 clinical trials of diabetes drugs and devices. Dr. Klonoff was the
lead investigator for the first randomized controlled multicenter trial
of an outpatient artificial pancreas product and published the results
in the New England Journal of Medicine. He was an advisor and/or
investigator for the first, second, third, and fourth CE-marked
noninvasive glucose monitors. He founded the Diabetes Technology Meeting
and the Digital Diabetes Congress.

Dr. Klonoff has served on 56 grant review panels including for NIH, CDC,
NASA, NSF, US Army, NOAA, ADA, and JDRF; plus, agencies in nine foreign
countries. He chairs the Scientific Advisory Board of the Texas
A&M/UCLA/FIU/Rice PATHS-UP Engineering Research Center and the CLSI
Continuous Glucose Monitor technical guideline committee, POCT05. He is
an affiliate member of the Baylor University Center for Space Medicine.
Dr. Klonoff is a member of the Healthcare Sector Coordinating Council
Joint Cyber Working Group for Medical Devices/Healthcare. He chaired
DTSec and DTMoSt, the world’s 1st and 2nd consensus medical device
cybersecurity standards. For this work Dr. Klonoff was featured in an
article in Wired Magazine.

About Know Labs, Inc.

Know Labs, Inc. is a public company whose shares trade under the stock
symbol “KNWN.” The company’s technology directs structured light or
radio waves through a substance or material to capture a unique
molecular signature. The Company refers to these signatures as ChromaID™
and Bio-RFID™. ChromaID and Bio-RFID are used to identify, detect, or
diagnose substance markers or biomarkers that may be invisible to the
human eye. ChromaID and Bio-RFID scanner modules can be integrated into
a variety of wearable, mobile or bench-top form factors. This patented
and patent pending, award-winning technology makes it possible to
effectively conduct analyses that could only previously be performed by
invasive and/or large and expensive lab-based tests. For more
information on Know Labs, visit the company’s website at

Safe Harbor Statement

This release contains statements that constitute forward-looking
statements within the meaning of Section 27A of the Securities Act of
1933, as amended, and Section 21E of the Securities Exchange Act of
1934, as amended. These statements appear in a number of places in this
release and include all statements that are not statements of historical
fact regarding the intent, belief or current expectations of Know Labs,
Inc., its directors or its officers with respect to, among other things:
(i) financing plans; (ii) trends affecting its financial condition or
results of operations; (iii) growth strategy and operating strategy. The
words may, would, will, expect, estimate, can, believe, potential and
similar expressions and variations thereof are intended to identify
forward-looking statements. Investors are cautioned that any such
forward-looking statements are not guarantees of future performance and
involve risks and uncertainties, many of which are beyond Know Labs,
Inc.’s ability to control, and actual results may differ materially from
those projected in the forward-looking statements as a result of various